Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results